Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 5/20 | 0.50 |
| ▸ | CA1 | P00915 | 4/20 | 0.50 |
| ▸ | CA2 | P00918 | 4/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA7 | P43166 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | PDK1 | Q15118 | 2/20 | 0.47 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.47 |
| ▸ | PDK3 | Q15120 | 2/20 | 0.47 |
| ▸ | PDK4 | Q16654 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | CASP3 | P42574 | 1/20 | 0.46 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14344210 | 0.94 | TSHR (0.46) | HSD11B1CA1CA2MAPTTDP1 | |
| SCHEMBL12489762 | 0.90 | MAPT (0.47) | CA1CA2MAPTTDP1CA12 | |
| SCHEMBL14344211 | 0.89 | HSD11B1 (0.43) | HSD11B1CA1CA2MAPTTDP1 | |
| SCHEMBL18388586 | 0.85 | CA1 (0.53) | CA1CA2MAPTTDP1CA12 | |
| SCHEMBL264109 | 0.84 | CYP17A1 (0.50) | HSD11B1CA1CA2CA12CA7 | |
| SCHEMBL15528792 | 0.84 | CA1 (0.52) | CA1CA2MAPTTDP1CA12 | |
| SCHEMBL1033729 | 0.84 | MLYCD (0.61) | CA1CA2MAPTTDP1CA12 | |
| SCHEMBL8336883 | 0.83 | CA1 (0.55) | CA1CA2MAPTTDP1CA12 | |
| SCHEMBL2549591 | 0.83 | CA1 (0.55) | CA1CA2MAPTTDP1CA12 | |
| SCHEMBL8928305 | 0.81 | CA1 (0.53) | CA1CA2MAPTTDP1CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3623372-B1 | PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | VALO HEALTH INC (US) | 2026-02-04 | — | — | EP | disclosed |
| US-12018030-B2 | Pyrrolo and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitors | VALO HEALTH, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| CN-111233863-B | Hydroxyl purine compound and application thereof | 广东众生睿创生物科技有限公司 | 2022-10-25 | — | — | CN | disclosed |
| US-RE49128-E1 | Hydroxyl purine compounds and applications thereof | Guangdong Raynovent Biotech Co., Ltd. (CN) | 2022-07-12 | — | — | US | disclosed |
| US-RE49128-E1 | Hydroxyl purine compounds and applications thereof | Guangdong Raynovent Biotech Co., Ltd. (CN) | 2022-07-12 | — | — | US | disclosed |
| EP-3205652-B1 | HYDROXYL PURINE COMPOUNDS AND APPLICATIONS THEREOF | GUANGDONG RAYNOVENT BIOTECH CO LTD (CN) | 2022-03-09 | — | — | EP | disclosed |
| US-20210332052-A1 | PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | VALO HEALTH, INC. | 2021-10-28 | — | — | US | disclosed |
| US-20210332052-A1 | PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | VALO HEALTH, INC. | 2021-10-28 | — | — | US | disclosed |
| CN-108430974-B | ROR gamma modulators | 领先制药控股公司 | 2021-09-17 | — | — | CN | disclosed |
| CN-108348525-B | Medical application of hydroxyl purine compound | 广东众生睿创生物科技有限公司 | 2021-09-10 | — | — | CN | disclosed |
| US-20070299080-A1 | N-Benzyl-N-methyl-4-(1,1,1-trifluoro-2-hydroxypropan-2-yl)benzamide; modulating activity of hydroxysteroid dehydrogenases (HSDs), 11 beta-hydroxysteroid dehydrogenases,(also; 17 beta-, 20 alpha-, and 3 alpha-); antidiabetic agents;, obesity, glaucoma, osteoporosis, cognitive disorders; immunotherapy | AMGEN INC. | 2007-12-27 | — | — | US | disclosed |
| US-20070299080-A1 | N-Benzyl-N-methyl-4-(1,1,1-trifluoro-2-hydroxypropan-2-yl)benzamide; modulating activity of hydroxysteroid dehydrogenases (HSDs), 11 beta-hydroxysteroid dehydrogenases,(also; 17 beta-, 20 alpha-, and 3 alpha-); antidiabetic agents;, obesity, glaucoma, osteoporosis, cognitive disorders; immunotherapy | AMGEN INC. | 2007-12-27 | — | — | US | disclosed |
| US-20070299080-A1 | N-Benzyl-N-methyl-4-(1,1,1-trifluoro-2-hydroxypropan-2-yl)benzamide; modulating activity of hydroxysteroid dehydrogenases (HSDs), 11 beta-hydroxysteroid dehydrogenases,(also; 17 beta-, 20 alpha-, and 3 alpha-); antidiabetic agents;, obesity, glaucoma, osteoporosis, cognitive disorders; immunotherapy | AMGEN INC. | 2007-12-27 | — | — | US | disclosed |
| US-20070299111-A1 | N-Benzyl-N-methyl-4-(1,1,1-trifluoro-2-hydroxypropan-2-yl)benzamide; modulating activity of hydroxysteroid dehydrogenases (HSDs), 11 beta-hydroxysteroid dehydrogenases,(also; 17 beta-, 20 alpha-, and 3 alpha-); antidiabetic agents;, obesity, glaucoma, osteoporosis, cognitive disorders; immunotherapy | AMGEN INC. | 2007-12-27 | — | — | US | disclosed |
| WO-2007145835-A2 | BENZAMIDE DERIVATIVES AS MODULATORS OF 11BETA-HSD1 FOR TREATING DIABETES AND OBESITY | AMGEN INC. (US) | 2007-12-21 | — | — | WO | disclosed |
| WO-2007145835-A2 | BENZAMIDE DERIVATIVES AS MODULATORS OF 11BETA-HSD1 FOR TREATING DIABETES AND OBESITY | AMGEN INC. (US) | 2007-12-21 | — | — | WO | disclosed |
| WO-2007145834-A2 | BENZAMIDE DERIVATIVES AND USES RELATED THERETO | AMGEN INC. (US) | 2007-12-21 | — | — | WO | disclosed |
| WO-2007145834-A2 | BENZAMIDE DERIVATIVES AND USES RELATED THERETO | AMGEN INC. (US) | 2007-12-21 | — | — | WO | disclosed |
| US-20060293392-A1 | Benzamide derivatives and uses related thereto | AMGEN INC. | 2006-12-28 | — | — | US | disclosed |
| WO-2006138508-A2 | BENZAMIDE DERIVATIVES AND USES RELATED THERETO | AMGEN INC. (US) | 2006-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070299111-A1 | N-Benzyl-N-methyl-4-(1,1,1-trifluoro-2-hydroxypropan-2-yl)benzamide; modulating activity of hydroxysteroid dehydrogenases (HSDs), 11 beta-hydroxysteroid dehydrogenases,(also; 17 beta-, 20 alpha-, and 3 alpha-); antidiabetic agents;, obesity, glaucoma, osteoporosis, cognitive disorders; immunotherapy | HSD17B1, HSD3B1, HSD11B1 | HSD11B1 3/4885CA1 2312/4885CA2 1837/4885 |
| US-12018030-B2 | Pyrrolo and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitors | USP7, UBA7, UBXN1 | HSD11B1 4118/4885CA1 3636/4885CA2 4706/4885 |
| US-20210332052-A1 | PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | USP7, UBA7, UBXN1 | HSD11B1 4118/4885CA1 3636/4885CA2 4706/4885 |
| US-20060293392-A1 | Benzamide derivatives and uses related thereto | GPR119, GLP1R, UGT2B7 | HSD11B1 1333/4885CA1 4170/4885CA2 1948/4885 |
| US-20070299080-A1 | N-Benzyl-N-methyl-4-(1,1,1-trifluoro-2-hydroxypropan-2-yl)benzamide; modulating activity of hydroxysteroid dehydrogenases (HSDs), 11 beta-hydroxysteroid dehydrogenases,(also; 17 beta-, 20 alpha-, and 3 alpha-); antidiabetic agents;, obesity, glaucoma, osteoporosis, cognitive disorders; immunotherapy | HSD3B1, HSD17B1, HSD3B2 | HSD11B1 4/4885CA1 2665/4885CA2 2392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.